India Cements Ltd Share Price – NSE /  BSE

Cement, Small Cap

Revenue from operations declined 3.87% year-on-year (YoY) to Rs 1,197.13 crore in Q4 FY25, compared to Rs 1,245.38 crore in the same period last year.

The company reported a pre-tax loss of Rs 101.13 crore in Q4 FY25, compared to a pre-tax loss of Rs 32.91 crore recorded in the same period a year ago. The firm reported exceptional items of Rs 2.70 crore during the quarter.

Total expenses were largely flat, inching up just 0.02% YoY to Rs 1,319.10 crore. Employee benefits expense declined 8.72% YoY to Rs 89.39 crore, while finance costs dropped 25.31% YoY to Rs 47.60 crore.

On a consolidated basis, the company?s net profit stood at Rs 19.41 crore in Q4 FY25 as against a net loss of Rs 50.06 in Q4 FY24. Revenue from operations stood at Rs 1,197.30 crore in the fourth quarter of FY25, down 3.19% as against Rs 1,236.74 crore posted in Q4 FY24.

India Cements business is the manufacturing and sale of cement and cement-related products.

Shares of India Cements shed 0.75% to Rs 285.80 on the BSE.

Powered by Capital Market - Live News

Net profit of India Cements reported to Rs 14.68 crore in the quarter ended March 2025 as against net loss of Rs 60.55 crore during the previous quarter ended March 2024. Sales declined 3.11% to Rs 1197.30 crore in the quarter ended March 2025 as against Rs 1235.74 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 143.68 crore in the year ended March 2025 as against net loss of Rs 227.36 crore during the previous year ended March 2024. Sales declined 16.99% to Rs 4148.78 crore in the year ended March 2025 as against Rs 4997.85 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

The Board of India Cements at its meeting held on 18 March 2025 has approved the following:

1. Sale of its entire equity investment in Coromandel Travels (CTL), a subsidiary of the Company. Upon completion of the said sale, CTL would cease to be a subsidiary.

2. Sale of its entire equity investment in Raasi Cement (RCL), an associate of the Company.

The Board also noted that ICL Financial Services (ICLFSL) and ICL Securities (ICLSL), wholly-owned subsidiaries of the Company, have approved: -

1. Sale of their entire equity investment in Raasi Cement, an associate of the Company. Upon completion of the said sale, Raasi Cement will cease to be an associate of the Company.

2. Sale of their entire equity investment in Coromandel Electric Company (CECL), a subsidiary of the Company. Upon completion of the said sale, CECL would cease to be a subsidiary of the Company. Further, Coromandel Sugars, an associate company in which CECL holds 49.99% of equity shares, would also cease to be an associate of the Company.

3. Sale of their entire equity investment in Unique Receivables Management (Unique Receivables), an associate of the Company. Upon completion of the said sale, Unique Receivables would cease to be an associate of the Company.

Powered by Capital Market - Live News

Net profit of India Cements reported to Rs 14.68 crore in the quarter ended March 2025 as against net loss of Rs 60.55 crore during the previous quarter ended March 2024. Sales declined 3.11% to Rs 1197.30 crore in the quarter ended March 2025 as against Rs 1235.74 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 143.68 crore in the year ended March 2025 as against net loss of Rs 227.36 crore during the previous year ended March 2024. Sales declined 16.99% to Rs 4148.78 crore in the year ended March 2025 as against Rs 4997.85 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

The Board of India Cements at its meeting held on 18 March 2025 has approved the following:

1. Sale of its entire equity investment in Coromandel Travels (CTL), a subsidiary of the Company. Upon completion of the said sale, CTL would cease to be a subsidiary.

2. Sale of its entire equity investment in Raasi Cement (RCL), an associate of the Company.

The Board also noted that ICL Financial Services (ICLFSL) and ICL Securities (ICLSL), wholly-owned subsidiaries of the Company, have approved: -

1. Sale of their entire equity investment in Raasi Cement, an associate of the Company. Upon completion of the said sale, Raasi Cement will cease to be an associate of the Company.

2. Sale of their entire equity investment in Coromandel Electric Company (CECL), a subsidiary of the Company. Upon completion of the said sale, CECL would cease to be a subsidiary of the Company. Further, Coromandel Sugars, an associate company in which CECL holds 49.99% of equity shares, would also cease to be an associate of the Company.

3. Sale of their entire equity investment in Unique Receivables Management (Unique Receivables), an associate of the Company. Upon completion of the said sale, Unique Receivables would cease to be an associate of the Company.

Powered by Capital Market - Live News

Schaeffler India Ltd, Astrazeneca Pharma India Ltd, Jyoti CNC Automation Ltd, Concord Biotech Ltd are among the other stocks to see a surge in volumes on NSE today, 04 March 2025.

India Cements Ltd recorded volume of 67.31 lakh shares by 14:14 IST on NSE, a 11.95 times surge over two-week average daily volume of 5.63 lakh shares. The stock gained 11.67% to Rs.286.50. Volumes stood at 7.07 lakh shares in the last session.

Schaeffler India Ltd recorded volume of 4.48 lakh shares by 14:14 IST on NSE, a 8.61 times surge over two-week average daily volume of 52060 shares. The stock gained 4.62% to Rs.3,229.90. Volumes stood at 51882 shares in the last session.

Astrazeneca Pharma India Ltd registered volume of 69196 shares by 14:14 IST on NSE, a 7.21 fold spurt over two-week average daily volume of 9598 shares. The stock rose 6.77% to Rs.7,322.60. Volumes stood at 13811 shares in the last session.

Jyoti CNC Automation Ltd saw volume of 58.85 lakh shares by 14:14 IST on NSE, a 6.73 fold spurt over two-week average daily volume of 8.74 lakh shares. The stock increased 12.75% to Rs.869.00. Volumes stood at 6.96 lakh shares in the last session.

Concord Biotech Ltd recorded volume of 7.02 lakh shares by 14:14 IST on NSE, a 5.94 times surge over two-week average daily volume of 1.18 lakh shares. The stock gained 13.87% to Rs.1,732.45. Volumes stood at 81181 shares in the last session.

Powered by Capital Market - Live News

Revenue from operations declined 3.87% year-on-year (YoY) to Rs 1,197.13 crore in Q4 FY25, compared to Rs 1,245.38 crore in the same period last year.

The company reported a pre-tax loss of Rs 101.13 crore in Q4 FY25, compared to a pre-tax loss of Rs 32.91 crore recorded in the same period a year ago. The firm reported exceptional items of Rs 2.70 crore during the quarter.

Total expenses were largely flat, inching up just 0.02% YoY to Rs 1,319.10 crore. Employee benefits expense declined 8.72% YoY to Rs 89.39 crore, while finance costs dropped 25.31% YoY to Rs 47.60 crore.

On a consolidated basis, the company?s net profit stood at Rs 19.41 crore in Q4 FY25 as against a net loss of Rs 50.06 in Q4 FY24. Revenue from operations stood at Rs 1,197.30 crore in the fourth quarter of FY25, down 3.19% as against Rs 1,236.74 crore posted in Q4 FY24.

India Cements business is the manufacturing and sale of cement and cement-related products.

Shares of India Cements shed 0.75% to Rs 285.80 on the BSE.

Powered by Capital Market - Live News

Net profit of India Cements reported to Rs 14.68 crore in the quarter ended March 2025 as against net loss of Rs 60.55 crore during the previous quarter ended March 2024. Sales declined 3.11% to Rs 1197.30 crore in the quarter ended March 2025 as against Rs 1235.74 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 143.68 crore in the year ended March 2025 as against net loss of Rs 227.36 crore during the previous year ended March 2024. Sales declined 16.99% to Rs 4148.78 crore in the year ended March 2025 as against Rs 4997.85 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

The Board of India Cements at its meeting held on 18 March 2025 has approved the following:

1. Sale of its entire equity investment in Coromandel Travels (CTL), a subsidiary of the Company. Upon completion of the said sale, CTL would cease to be a subsidiary.

2. Sale of its entire equity investment in Raasi Cement (RCL), an associate of the Company.

The Board also noted that ICL Financial Services (ICLFSL) and ICL Securities (ICLSL), wholly-owned subsidiaries of the Company, have approved: -

1. Sale of their entire equity investment in Raasi Cement, an associate of the Company. Upon completion of the said sale, Raasi Cement will cease to be an associate of the Company.

2. Sale of their entire equity investment in Coromandel Electric Company (CECL), a subsidiary of the Company. Upon completion of the said sale, CECL would cease to be a subsidiary of the Company. Further, Coromandel Sugars, an associate company in which CECL holds 49.99% of equity shares, would also cease to be an associate of the Company.

3. Sale of their entire equity investment in Unique Receivables Management (Unique Receivables), an associate of the Company. Upon completion of the said sale, Unique Receivables would cease to be an associate of the Company.

Powered by Capital Market - Live News

Net profit of India Cements reported to Rs 14.68 crore in the quarter ended March 2025 as against net loss of Rs 60.55 crore during the previous quarter ended March 2024. Sales declined 3.11% to Rs 1197.30 crore in the quarter ended March 2025 as against Rs 1235.74 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 143.68 crore in the year ended March 2025 as against net loss of Rs 227.36 crore during the previous year ended March 2024. Sales declined 16.99% to Rs 4148.78 crore in the year ended March 2025 as against Rs 4997.85 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

The Board of India Cements at its meeting held on 18 March 2025 has approved the following:

1. Sale of its entire equity investment in Coromandel Travels (CTL), a subsidiary of the Company. Upon completion of the said sale, CTL would cease to be a subsidiary.

2. Sale of its entire equity investment in Raasi Cement (RCL), an associate of the Company.

The Board also noted that ICL Financial Services (ICLFSL) and ICL Securities (ICLSL), wholly-owned subsidiaries of the Company, have approved: -

1. Sale of their entire equity investment in Raasi Cement, an associate of the Company. Upon completion of the said sale, Raasi Cement will cease to be an associate of the Company.

2. Sale of their entire equity investment in Coromandel Electric Company (CECL), a subsidiary of the Company. Upon completion of the said sale, CECL would cease to be a subsidiary of the Company. Further, Coromandel Sugars, an associate company in which CECL holds 49.99% of equity shares, would also cease to be an associate of the Company.

3. Sale of their entire equity investment in Unique Receivables Management (Unique Receivables), an associate of the Company. Upon completion of the said sale, Unique Receivables would cease to be an associate of the Company.

Powered by Capital Market - Live News

Schaeffler India Ltd, Astrazeneca Pharma India Ltd, Jyoti CNC Automation Ltd, Concord Biotech Ltd are among the other stocks to see a surge in volumes on NSE today, 04 March 2025.

India Cements Ltd recorded volume of 67.31 lakh shares by 14:14 IST on NSE, a 11.95 times surge over two-week average daily volume of 5.63 lakh shares. The stock gained 11.67% to Rs.286.50. Volumes stood at 7.07 lakh shares in the last session.

Schaeffler India Ltd recorded volume of 4.48 lakh shares by 14:14 IST on NSE, a 8.61 times surge over two-week average daily volume of 52060 shares. The stock gained 4.62% to Rs.3,229.90. Volumes stood at 51882 shares in the last session.

Astrazeneca Pharma India Ltd registered volume of 69196 shares by 14:14 IST on NSE, a 7.21 fold spurt over two-week average daily volume of 9598 shares. The stock rose 6.77% to Rs.7,322.60. Volumes stood at 13811 shares in the last session.

Jyoti CNC Automation Ltd saw volume of 58.85 lakh shares by 14:14 IST on NSE, a 6.73 fold spurt over two-week average daily volume of 8.74 lakh shares. The stock increased 12.75% to Rs.869.00. Volumes stood at 6.96 lakh shares in the last session.

Concord Biotech Ltd recorded volume of 7.02 lakh shares by 14:14 IST on NSE, a 5.94 times surge over two-week average daily volume of 1.18 lakh shares. The stock gained 13.87% to Rs.1,732.45. Volumes stood at 81181 shares in the last session.

Powered by Capital Market - Live News